Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 5Rituximab 4Mycophenolic Acid 4Cyclosporine 4Cyclophosphamide 4romidepsin 3Whole-Body Irradiation 3Methotrexate 3Everolimus 3Busulfan 3durvalumab 2Vorinostat 2Vincristine 2Tacrolimus 2Photopheresis 2Immunoglobulin G 2Filgrastim 2Etoposide 2Disulfides 2Brentuximab Vedotin 2Bortezomib 2veliparib 1tremelimumab 1tazarotenic acid 1tazarotene 1poly ICLC 1pembrolizumab 1navitoclax 1mogamulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Cutaneous × Aclarubicin × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡